키토산 시장 : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the chitosan market size is estimated at USD 6.30 billion in 2026, and is expected to reach USD 11.30 billion by 2031, at a CAGR of 12.38% during the forecast period (2026-2031).

This report is Segmented by Source (Shrimps, Crabs, and More), Grade (Industrial Grade, Food Grade, and More), Form (Powder, Flake, and More), Application (Water Treatment, Cosmetics and Personal Care, and More), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The Market Research Report Offers the Value (in USD) for the Above Segments.

Global Chitosan Market Trends and Insights

Rising Water-Treatment Regulations

Utilities in the European Union must now install quaternary treatment that targets micropollutants, and chitosan simultaneously coagulates colloids and adsorbs trace organics, reducing alum use by up to 30%. Industrial sites in the United States face stricter 40 CFR Part 125 limits for heavy metals, and chitosan derivatives remove 93-99% of iron, copper and zinc without hazardous sludge. China has cut total chromium limits for electroplating effluent to 0.5 mg L-1, prompting early adoption of chitosan flocculants in Zhejiang and Guangdong. These converging regulations enlarge the addressable market for high-deacetylation chitosan grades that assure both performance and biodegradability.

Surging Demand for Biodegradable and Eco-Friendly Materials

Brand owners pursuing plastic-free packaging and compostable agriculture inputs are specifying chitosan films that degrade 80-90% within 60 days under industrial composting, far faster than polyethylene. The Single-Use Plastics Directive in Europe curbs oxo-degradable polymers, directing formulators toward chitosan seed coatings and controlled-release fertilizers that leave no persistent residue. Hair-care brands are reformulating gels with quaternized chitosan that delivers hold without microplastics, leveraging marine-origin storytelling to command premium shelf pricing. These preferences move the global chitosan market beyond compliance, turning biodegradability into a marketing advantage.

Allergenic Concerns Limiting Food and Cosmetic Uptake

Residual proteins in lower-grade crustacean chitosan can trigger IgE reactions in shellfish-sensitized individuals, leading the European Food Safety Authority to delay opinions on direct food contact and forcing cosmetic brands to label shellfish origin. Fungal and insect chitosan could bypass allergen labeling, but clinical safety dossiers remain incomplete, holding back full-scale commercialization. Until risk assessments conclude, formulators in mass-market foods and cosmetics will limit chitosan inclusion or invest in higher-purity grades, tempering near-term volume growth.

Other drivers and restraints analyzed in the detailed report include:

1. Expanding Biomedical, Cosmetics and Food Uses of Chitosan Oligosaccharides
2. Shift Toward Bio-Based Flocculants in Industrial Effluents
3. High Cost of Ultra-High-Purity Medical-Grade Chitosan

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Shrimp shells yielded 45.55% of global chitosan market output in 2025, supported by established logistics in Thailand, Vietnam and India that channel 1.5 million t of shell waste into dedicated deacetylation lines. Crabs are forecast to lead growth at a 13.25% CAGR as processors in Alaska and Northern Europe consolidate shell recovery, boosting deacetylation yields and lowering unit costs. Insect exoskeletons and fungal biomass are emerging feedstocks with vegan, Halal and Kosher positioning, yet extraction costs remain 20-30% higher owing to immature infrastructure. Seasonal variability still influences the global chitosan market, as climate anomalies shrink shrimp harvests in El Nino years, prompting processors to hedge supply with mixed crustacean and fungal inputs. Although squid-derived chitosan remains a niche, its clarity and low viscosity command premium pricing in high-end cosmetics, revealing the diversification potential within marine feedstocks.

Crab-based capacity expansions in Norway and Canada are backed by grants that subsidize cold-water fishery waste valorization, reinforcing supply security for European buyers seeking traceability under the EU Green Deal. Asian government incentives for insect farming on food waste are likewise nurturing pilot-scale black soldier fly chitosan plants, opening a circular-economy storyline. While insect chitosan currently represents less than 2% of global chitosan market volume, favorable life-cycle assessments could accelerate its share once purification costs fall. Overall, feedstock diversification limits raw-material risk and supports stable pricing in a market vulnerable to aquaculture disease outbreaks.

Industrial-grade material commanded 45.53% of the global chitosan market size in 2025, filling water-treatment and textile niches where 75-85% deacetylation suffices. Pharmaceutical and biomedical grades, however, will outpace commodity specifications at 12.85% CAGR through 2031 as clinical evidence spreads and military procurement of hemostatic dressings rises. The degree of deacetylation, endotoxin burden and molecular-weight range define price tiers, with Good Manufacturing Practice batches retailing at 3-10 times industrial equivalents.

Drug-carrier patents covering chitosan-collagen composites and nano-gel matrices strengthen price resilience, while oligopolistic supply from Primex, Heppe Medical Chitosan and a few Chinese DMF holders preserves market discipline. Food-grade chitosan, positioned between industrial and medical benchmarks, benefits from Generally Recognized as Safe status in the United States yet awaits full clearance in Europe. As a result, the grade hierarchy widens, segmenting buyers by regulatory exposure and margin appetite rather than sheer volume requirements.

Complete Report Scope:

• By Source
  • Shrimps
  • Crabs
  • Squid
  • Fungi / Mycelium
  • Insect Exoskeletons
  • Others
• By Grade
  • Industrial Grade
  • Food Grade
  • Pharmaceutical & Biomedical Grade
• By Form
  • Powder
  • Flake
  • Liquid
  • Nano / Micro Particles
• By Application
  • Water Treatment
  • Cosmetics & Personal Care
  • Pharmaceutical & Biomedical
  • Food & Beverage
  • Agriculture & Horticulture
  • Textile & Printing
  • Others
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

Europe will post the strongest 14.51% CAGR through 2031, propelled by quaternary wastewater mandates and the biostimulant classification that simplifies chitosan deployment in farming. Germany funds municipal trials that replace polyacrylamide with chitosan, and Spain deploys chitosan sprays in viticulture to reduce synthetic fungicide load. United Kingdom trauma centers have standardized chitosan dressings, boosting hospital demand and reinforcing the region's leadership in medical applications.

North America captured 25.13% of global chitosan market share in 2025, anchored by EPA pretreatment standards and early battlefield use of chitosan hemostats. Growth moderates as water-treatment installations mature, yet pharmaceutical prospects remain attractive as inhaled-drug-grade chitosan wins its first USP monograph. Canada's cold-water crab fisheries provide low-contaminant shells, supporting premium pharmaceutical supply chains and reinforcing regional competitiveness.

Asia-Pacific supplies most feedstock, processing about 2 million t of shell waste annually in Thailand, Vietnam and China. Domestic chitosan uptake is uneven; China tightened chromium discharge limits, catalyzing localized adoption, but enforcement gaps restrain nationwide penetration. Japan specializes in cosmetic-grade oligosaccharides with proprietary hydrolysis technology, while India's aquaculture hubs expand industrial-grade output for global export. Emerging markets in the Middle East test chitosan as a pretreatment in desalination, and South America inches forward with Brazil deploying chitosan bio-pesticides in organic soy farming amid tariff and infrastructure headwinds.

1. Advanced Biopolymers AS
2. Bio21 AS
3. ChitoTech Co. Ltd
4. D'Labs Chemicals Pvt Ltd
5. Dainichiseika Color & Chemicals Mfg
6. Golden-Shell Pharmaceutical Co. Ltd
7. GTC Bio
8. Heppe Medical Chitosan
9. Japan BioKey Inc.
10. KIMICA
11. KitoZyme
12. Koyo World
13. Marsing & Co A/S
14. Meron Biopolymers
15. Panvo Organics
16. Primex ehf
17. Qingdao Yunzhou Biochemistry Co. Ltd
18. Tidal Vision Products Inc.
19. Zhejiang Aoxing Biotechnology Co. Ltd
20. Zhejiang Golden-Shell Biotechnology Co. Ltd

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rising water-treatment regulations
  • 4.2.2 Surging demand for biodegradable & eco-friendly materials
  • 4.2.3 Expanding biomedical, cosmetics & food uses of chitosan oligosaccharides
  • 4.2.4 Shift toward bio-based flocculants in industrial effluents
  • 4.2.5 Adoption of fungal/plant-based chitosan for vegan & Halal/Kosher markets
  • 4.2.6 Circular-economy valorization of seafood & insect waste streams
• 4.3 Market Restraints
  • 4.3.1 Allergenic concerns limiting food & cosmetic uptake
  • 4.3.2 High cost of ultra-high-purity medical-grade chitosan
  • 4.3.3 Limited scalability of fungal fermentation capacity
  • 4.3.4 Climate-driven volatility of crustacean biomass supply
• 4.4 Value / Supply-Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces
  • 4.7.1 Threat of New Entrants
  • 4.7.2 Bargaining Power of Buyers/Consumers
  • 4.7.3 Bargaining Power of Suppliers
  • 4.7.4 Threat of Substitute Products
  • 4.7.5 Intensity of Competitive Rivalry

5 Market Size & Growth Forecasts (Value, USD)

• 5.1 By Source
  • 5.1.1 Shrimps
  • 5.1.2 Crabs
  • 5.1.3 Squid
  • 5.1.4 Fungi / Mycelium
  • 5.1.5 Insect Exoskeletons
  • 5.1.6 Others
• 5.2 By Grade
  • 5.2.1 Industrial Grade
  • 5.2.2 Food Grade
  • 5.2.3 Pharmaceutical & Biomedical Grade
• 5.3 By Form
  • 5.3.1 Powder
  • 5.3.2 Flake
  • 5.3.3 Liquid
  • 5.3.4 Nano / Micro Particles
• 5.4 By Application
  • 5.4.1 Water Treatment
  • 5.4.2 Cosmetics & Personal Care
  • 5.4.3 Pharmaceutical & Biomedical
  • 5.4.4 Food & Beverage
  • 5.4.5 Agriculture & Horticulture
  • 5.4.6 Textile & Printing
  • 5.4.7 Others
• 5.5 By Geography
  • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
  • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
  • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 Japan
    • 5.5.3.3 India
    • 5.5.3.4 Australia
    • 5.5.3.5 South Korea
    • 5.5.3.6 Rest of Asia-Pacific
  • 5.5.4 Middle East & Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East & Africa
  • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
  • 6.3.1 Advanced Biopolymers AS
  • 6.3.2 Bio21 AS
  • 6.3.3 ChitoTech Co. Ltd
  • 6.3.4 D'Labs Chemicals Pvt Ltd
  • 6.3.5 Dainichiseika Color & Chemicals Mfg Co. Ltd
  • 6.3.6 Golden-Shell Pharmaceutical Co. Ltd
  • 6.3.7 GTC Bio Corporation
  • 6.3.8 Heppe Medical Chitosan GmbH
  • 6.3.9 Japan BioKey Inc.
  • 6.3.10 KIMICA Corporation
  • 6.3.11 KitoZyme SA
  • 6.3.12 Koyo World
  • 6.3.13 Marsing & Co A/S
  • 6.3.14 Meron Biopolymers
  • 6.3.15 Panvo Organics Pvt Ltd
  • 6.3.16 Primex ehf
  • 6.3.17 Qingdao Yunzhou Biochemistry Co. Ltd
  • 6.3.18 Tidal Vision Products Inc.
  • 6.3.19 Zhejiang Aoxing Biotechnology Co. Ltd
  • 6.3.20 Zhejiang Golden-Shell Biotechnology Co. Ltd

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-Need Assessment